Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1343538

registered interest
date	05/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus and Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether covid-19 booster vaccines and flu vaccines will be delivered (a) at the same time and (b) in pharmacies.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	27158
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice on a potential COVID-19 booster vaccination programme on 30 June, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022" target="_blank">https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022</a></p><p>The JCVI recommends a two staged approach is recommended, with those in the first stage offered a booster and flu vaccine as soon as possible from September. Those in the second stage would be offered a booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible.</p><p>Final decisions on the timing and scope of the vaccine booster programme, as well as cohorts and eligibility, will be made later in the year, informed by further independent advice from the JCVI. This includes further data on the durability of protection from vaccines, data supplied by manufacturers and clinical trial data regarding COVID-19 vaccine and flu vaccine coadministration. On 1 July, NHS England and NHS Improvement wrote to primary care providers, including community pharmacies, outlining the JCVI’s interim advice to allow local planning to begin.</p><p> </p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 13/07/2021 16:05:46 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4131 label Biography information for Jim Shannon

1343576

registered interest
date	05/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the covid-19 vaccine status of (a) people who die within 28 days of a positive covid-19 test and (b) new covid-19 infections.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	27056
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>Public Health England (PHE) monitors the number of people who have been admitted to hospital and died from COVID-19 who have received one or two doses of the vaccine and will publish this data in due course. This includes the number of new cases of COVID-19 infection following vaccination.</p><p>PHE has not made a specific assessment of the potential effect of publishing information on the COVID-19 vaccine status of people who die within 28 days of a positive COVID-19 test and new COVID-19 infections on rates of vaccine uptake.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 27057 question first answered 13/07/2021 12:41:51 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 12675 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1522 label Biography information for Adam Holloway

1343577

registered interest
date	05/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of publishing information on the covid-19 vaccine status of (a) people who die within 28 days of a positive Covid test and (b) new covid-19 infections on rates of vaccine uptake.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	27057
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>Public Health England (PHE) monitors the number of people who have been admitted to hospital and died from COVID-19 who have received one or two doses of the vaccine and will publish this data in due course. This includes the number of new cases of COVID-19 infection following vaccination.</p><p>PHE has not made a specific assessment of the potential effect of publishing information on the COVID-19 vaccine status of people who die within 28 days of a positive COVID-19 test and new COVID-19 infections on rates of vaccine uptake.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 27056 question first answered 13/07/2021 12:41:52 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 12676 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1522 label Biography information for Adam Holloway

1343339

registered interest
date	02/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 June 2021 to Question 6412 on Coronavirus: Vaccination, when his Department plans to publish the vaccine strategy.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	26109
answer	answer is ministerial correction date of answer 15/07/2021 answer text <p>We are currently reviewing the proposed timetable for publication and we will provide more information in due course.</p><p> </p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/07/2021 15:35:38 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 12355 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380
tabling member	4249 label Biography information for Anne Marie Morris

1342296

registered interest
date	30/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what data his Department holds on the effectiveness of the (a) Pfizer, (b) AstraZeneca and (c) Moderna covid-19 vaccinations at reducing transmission of covid-19.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	25123
answer	answer is ministerial correction date of answer 15/07/2021 answer text <p>Public Health England (PHE) publishes weekly COVID-19 vaccine surveillance reports which include the latest evidence on vaccine effectiveness against different outcomes. The following table shows the latest summary of evidence on vaccine effectiveness against different outcomes, including transmission, for Pfizer/BioNTech and University of Oxford/AstraZeneca as of 1 July.</p><p> </p><table><tbody><tr><td rowspan="3"><p>Outcome</p></td><td colspan="4"><p>Vaccine Effectiveness</p></td></tr><tr><td colspan="2"><p>Pfizer/BioNTech</p></td><td colspan="2"><p>Oxford/AstraZeneca</p></td></tr><tr><td><p>1 dose</p></td><td><p>2 doses</p></td><td><p>1 dose</p></td><td><p>2 doses</p></td></tr><tr><td><p>Symptomatic disease</p></td><td><p>55-70%*</p></td><td><p>85-95%*</p></td><td><p>55-70%*</p></td><td><p>70-85%**</p></td></tr><tr><td><p>Hospitalisation</p></td><td><p>75-85%*</p></td><td><p>90-99%**</p></td><td><p>75-85%*</p></td><td><p>80-99%***</p></td></tr><tr><td><p>Mortality</p></td><td><p>70-80%**</p></td><td><p>95-99%**</p></td><td><p>75-85%**</p></td><td><p>75-99%***</p></td></tr><tr><td><p>Infection</p></td><td><p>55-70%**</p></td><td><p>70-90%***</p></td><td><p>60-70%***</p></td><td><p>No data</p></td></tr><tr><td><p>Transmission (secondary cases)^</p></td><td><p>45-50%***</p></td><td><p>No data</p></td><td><p>35-50%***</p></td><td><p>No data</p></td></tr></tbody></table><p>Source: Table 3 <a href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fcovid-19-vaccine-surveillance-report&amp;data=04%7C01%7Ccovid19surv%40phe.gov.uk%7Cb2598e32058644d021bf08d916c0fea2%7Cee4e14994a354b2ead475f3cf9de8666%7C0%7C0%7C637565840415583246%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&amp;sdata=MFmH8qQxqsBUGSNXnO5e7tyCyPWBtYpuq%2FF3GUfu6AI%3D&amp;reserved=0" target="_blank">https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report</a></p><p> </p><p> </p><p>Notes:</p><ol><li>*High Confidence - Evidence from multiple studies which is consistent and comprehensive</li><li>**Medium Confidence - Evidence is emerging from a limited number of studies or with a moderately level of uncertainty</li><li>***Low Confidence - Little evidence is available at present and results are inconclusive</li><li>^effectiveness in reducing symptomatic secondary cases in households of a symptomatic index case</li></ol><p> </p><p>PHE plans to publish vaccine effectiveness data for Moderna when more evidence becomes available.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/07/2021 15:34:06 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1340076

registered interest
date	24/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he is having with representatives of providers of covid-19 vaccination hubs on the future use of the systems established for the covid-19 vaccination programme.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	21972
answer	answer is ministerial correction date of answer 27/07/2021 answer text <p>We engage regularly with the COVID-19 vaccination programme to discuss its progress and future.</p><p>A lessons learned process is ongoing to look at how the systems behind the programme can be used in future. On 1 July, NHS England and NHS Improvement wrote to National Health service organisations setting out COVID-19 vaccination autumn/winter or phase three planning, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/07/C1327-covid-19-vaccination-autumn-winter-phase-3-planning.pdf" target="_blank">https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/07/C1327-covid-19-vaccination-autumn-winter-phase-3-planning.pdf</a></p><p>The letter highlights the delivery model for the potential booster vaccination programme and co-administration with the seasonal influenza vaccination programme. The letter acknowledges that mixed delivery models, with tailoring to community needs in partnership with local authorities, has played a critical role in reaching underserved communities. The letter recommends systems should deploy delivery models which both spread capacity across community pharmacy, vaccination centres and general practice whilst considering the best delivery access for local population requirements, making the most of community pharmacy, pop ups, mobile units and other approaches.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 27/07/2021 15:49:53 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4471 label Biography information for Rachael Maskell

1339363

registered interest
date	23/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of people who have developed a disability as a result of receiving the covid-19 vaccination.
tabling member constituency	Shipley
tabling member printed	Philip Davies
uin	21172
answer	answer is ministerial correction date of answer 19/07/2021 answer text <p>It is not possible at present to quantify the number of people left disabled as a result of a COVID-19 vaccination. Disability has a wide-ranging definition, including the length of time for which a condition persists. It should be noted that a report of an adverse drug reaction does not mean that it was caused by the drug or vaccine. Clinical decisions on whether a vaccine has caused a disability are considered on a case by case basis and will include consideration as to whether there may have been other factors involved, such as other pre-existing conditions. Any functionality outcomes for such patients evolve over time and depend on multiple factors such as type of adverse event that occurred, patient’s age and underlying conditions.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 15202 question first answered 19/07/2021 15:28:28 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1565 label Biography information for Sir Philip Davies

1333979

registered interest
date	14/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people have been left disabled as a result of a covid-19 vaccination.
tabling member constituency	Shipley
tabling member printed	Philip Davies
uin	15202
answer	answer is ministerial correction date of answer 19/07/2021 answer text <p>It is not possible at present to quantify the number of people left disabled as a result of a COVID-19 vaccination. Disability has a wide-ranging definition, including the length of time for which a condition persists. It should be noted that a report of an adverse drug reaction does not mean that it was caused by the drug or vaccine. Clinical decisions on whether a vaccine has caused a disability are considered on a case by case basis and will include consideration as to whether there may have been other factors involved, such as other pre-existing conditions. Any functionality outcomes for such patients evolve over time and depend on multiple factors such as type of adverse event that occurred, patient’s age and underlying conditions.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 21172 question first answered 19/07/2021 15:28:28 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1565 label Biography information for Sir Philip Davies

1329432

registered interest
date	04/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 May 2021 to Question 6161 on the vaccination status of people hospitalised with the Indian variant of covid-19, for what reason those essential data are not held centrally in the format requested; in what format those data are held centrally; and if he will make it his policy without further delay to (a) gather centrally and (b) subsequently release to the media each day the numbers of people that have been hospitalised with the Indian variant of covid-19 who are (i) vaccinated with (A) one and (B) both doses and (ii) unvaccinated against coronavirus.
tabling member constituency	New Forest East
tabling member printed	Dr Julian Lewis
uin	10131
answer	answer is ministerial correction date of answer 26/07/2021 answer text <p>Data concerning the numbers of people hospitalised with the Delta variant who have received one dose, two doses and are unvaccinated is collected centrally for inclusion in Public Health England’s (PHE) ‘Investigation of SARS-CoV-2 variants of concern: technical briefings’ which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201" target="_blank">https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201</a></p><p>This data was first included on 27 May and form part of ongoing surveillance and vaccine effectiveness monitoring activity. Public Health England collates data on COVID-19 cases, hospitalisations and COVID-19 vaccination status from a number of different data sources, including the Office for National Statistics, National Health Service trusts, private laboratories and Lighthouse Laboratories There are currently no plans to provide daily statistics due to varying reporting timelines of the data sources.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 26/07/2021 16:17:49 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 5147 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	54 label Biography information for Sir Julian Lewis